Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Antje Wegener"'
Autor:
Antje Wegener
Publikováno v:
Journal of Applied Arts & Health. 11:143-148
This article discusses my work as a therapeutic puppeteer in youth welfare contexts. The value of the projective material and symbols of puppetry are well known; I focus on puppetry for its dramatic content. The therapist is like a dramaturge: s/he r
Publikováno v:
Journal of chromatography. A. 1562
A new methodology is presented for two-dimensional liquid chromatography (2D-LC) separations of polymers. Active solvent modulation (ASM) was evaluated in its effectiveness to enhance solvent compatibility for both separation dimensions. As an exampl
Autor:
Matteo Carrabba, Kathy C. Tran, Michele Shannon, Geoffrey L. Uy, Max S. Topp, Jan K Davidson-Moncada, David A. Rizzieri, John E. Godwin, Jon M. Wigginton, Jichao Sun, Giovanni Martinelli, Gerwin Huls, Hanna Jean Khoury, Antje Wegener, Fabio Ciceri, Norbert Vey, Matthew C. Foster, John F. DiPersio
Publikováno v:
Journal of Clinical Oncology. 35:TPS7070-TPS7070
TPS7070 Background: MGD006/S80880 is a novel CD123 x CD3 DART molecule designed to target CD123-positive cells for recognition and elimination by CD3-expressing T lymphocytes as effector cells. CD123, the alpha chain of the interleukin 3 receptor (IL
Autor:
Maria E. Lai, Maria Domenica Cappellini, Antje Wegener, Raimund Hirschberg, Gian Luca Forni, Silvia Fracchia, Emmanuel Bouillaud, Dany Habr, Antonio Piga
Publikováno v:
British journal of haematology. 168(6)
Some patients with β thalassaemia experience non-progressive creatinine increases with deferasirox, mostly within normal limits; the mechanisms involved are not fully elucidated. The effects of deferasirox on renal haemodynamics, including glomerula
Autor:
Sue-zette Valera, Jorge Sierra, Florence Binlich, Stephen A. Strickland, Daniel J. DeAngelo, Richard F. Schlenk, Christoph Röllig, Tuli De, Bruno C. Medeiros, Robert K. Stuart, Antje Wegener, Enrique M. Ocio, Felicitas Thol, Song Mu, Alison R. Walker
Publikováno v:
Blood. 126:2553-2553
Background: For patients (pts) with acute myeloid leukemia (AML) with poor prognostic indicators, such as unfavorable cytogenetics or secondary AML, overall and event-free survival (EFS) rates are much worse, highlighting the critical need for more e
Autor:
Je-Hwan Lee, Huda Salman, Pierre Fenaux, Carlos Graux, Antje Wegener, David Valcárcel, Lucien Gazi, Zita Borbényi, Árpád Illés, Suddhasatta Acharyya, Guillermo Garcia-Manero, Daniel J. DeAngelo, Nancy Zhu, Jamie Cavenagh, Karen W.L. Yee, Oliver G. Ottmann, Giuliana Alimena, Mikkael A. Sekeres, Alan Macwhannell, Miklos Egyed, Reinhard Stauder, Florence Binlich
Publikováno v:
Blood. 126:2861-2861
Introduction: Azacitidine (AZA) is approved for the treatment of myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML). AZA has improved the overall survival (OS) of patients (pts) with higher-risk MDS, however, to a media
Autor:
Antonio Piga, Mohsen Saleh Elalfy, Khawla Belhoul, Yurdanur Kilinç, Yongrong Lai, Akif Yesilipek, Dudley J. Pennell, Yesim Aydinok, Amal El-Beshlawy, Dany Habr, John B. Porter, Junwu Shen, Antje Wegener
Publikováno v:
Blood. 122:1018-1018
Background Cardiac iron removal is relatively slow and patients with cardiac siderosis can take years to normalize cardiac T2* to >20 ms. Prospective comparison of iron chelators are mostly limited to studies of 1-yr duration. CORDELIA is a large ran
Autor:
Silverio Perrotta, M. Domenica Cappellini, Antonis Kattamis, Junwu Shen, Yesim Aydinok, Raffaella Origa, Antje Wegener, Vip Viprakasit, Yurdanur Kilinç, John B. Porter, Mohsen Saleh Elalfy, Dany Habr, Zeynep Karakas, Amal El-Beshlawy
Publikováno v:
Blood. 122:2257-2257
Background Transfusion-dependent patients with severe cardiac siderosis often require intensive iron chelation therapy for a limited time to facilitate rapid removal of iron from the heart, allowing patients to move from a high-risk (cardiac T2* Aim
Autor:
Antje Wegener, Dany Habr, Maria Eliana Lai, Gian Luca Forni, M. Domenica Cappellini, Emmanuel Bouillaud, Silvia Fracchia, Antonio Piga
Publikováno v:
Blood. 120:3257-3257
Abstract 3257 Background: In previous studies with deferasirox (Exjade®), some patients experienced dose-dependent, non-progressive increases in serum creatinine, mostly within normal limits and mostly reversible with dose reduction/interruption. Al